Review Compares Bevacizumab vs. Ranibizumab for Macular Degeneration

This article originally appeared here.
Review Compares Bevacizumab vs. Ranibizumab for Macular Degeneration
Review Compares Bevacizumab vs. Ranibizumab for Macular Degeneration

(HealthDay News) — The systemic safety of bevacizumab appears to be similar to that of ranibizumab as intravitreal therapy for neovascular age-related macular degeneration (AMD), according to research published online September 15 in The Cochrane Library.

Lorenzo Moja, MD, of the University of Milan, and colleagues conducted a review of the systemic safety of bevacizumab vs. ranibizumab for the intravitreal treatment of neovascular AMD. Data from nine randomized, controlled studies were included in the meta-analysis.

The researchers found that, at the maximum follow-up of one or two years, based on eight studies involving 3,338 participants, the estimated risk ratio (RR) of death for bevacizumab compared with ranibizumab was 1.10 (95 percent confidence interval [CI], 0.78–1.57; P=0.59; moderate-quality evidence). Based on event rates in the studies, the risk of death was 3.7% for bevacizumab and 3.4% for ranibizumab. Based on nine studies involving 3,665 participants, the estimated RR for all serious systemic adverse events (SSAEs) for bevacizumab compared with ranibizumab was 1.08 (95% CI, 0.90–1.31; P=0.41; low-quality evidence). Based on event rates in the studies, the risk of SSAEs was 24% for bevacizumab and 22.2% for ranibizumab.

"Our review found the systemic safety of bevacizumab for neovascular AMD to be similar to that of ranibizumab, except for gastrointestinal disorders, which was a part of a secondary analysis," the authors write.

Several authors were investigators in the trials included in this review.

Abstract
Full Text (subscription or payment may be required)

Loading links....